+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Portable inhaled methoxyflurane is feasible and safe for colonoscopy in subjects with morbid obesity and/or obstructive sleep apnea



Portable inhaled methoxyflurane is feasible and safe for colonoscopy in subjects with morbid obesity and/or obstructive sleep apnea



Endoscopy International Open 3(5): E487-E493



Colonoscopy with inhaled methoxyflurane (Penthrox) is well tolerated in unselected subjects and is not associated with respiratory depression. The aim of this prospective study was to compare the feasibility, safety, and post-procedural outcomes of portable methoxyflurane used as an analgesic agent during colonoscopy with those of anesthesia-assisted deep sedation (AADS) in subjects with morbid obesity and/or obstructive sleep apnea (OSA). The outcomes of 140 patients with morbid obesity/OSA who underwent colonoscopy with either Penthrox inhalation (n = 85; 46 men, 39 women; mean age 57.2 ± 1.1 years) or AADS (n = 55; 27 men, 28 women; mean age, 54.9 ± 1.1 years) were prospectively assessed. All Penthrox-assisted colonoscopies were successful, without any requirement for additional intravenous sedation. Compared with AADS, Penthrox was associated with a shorter total procedural time (24 ± 1 vs. 52 ± 1 minutes, P < 0.001), a lower incidence of hypotension (3 /85 vs. 23 /55, P < 0.001), and a lower incidence of respiratory desaturation (0 /85 vs. 14 /55, P < 0.001). The patients in the Penthrox group recovered more rapidly and were discharged much earlier than those in the AADS group (27 ± 2 vs. 97 ± 5 minutes, P < 0.0001). Of those who underwent colonoscopy with Penthrox, 90 % were willing to receive Penthrox again for colonoscopy. More importantly, of the patients who underwent colonoscopy with Penthrox and had had AADS for previous colonoscopy, 82 % (28 /34) preferred to receive Penthrox for future colonoscopies. Penthrox-assisted colonoscopy cost significantly less than colonoscopy with AADS ($ 332 vs. $ 725, P < 0.001), with a cost saving of approximately $ 400 for each additional complication avoided. Compared with AADS, Penthrox is highly feasible and safe in patients with morbid obesity/OSA undergoing colonoscopy and is associated with fewer cardiorespiratory complications. Because of the advantages of this approach in regard to procedural time, recovery time, and cost benefit in comparison with AADS, further evaluation in a randomized trial is warranted.

Accession: 058575973

Download citation: RISBibTeXText

PMID: 26528506

DOI: 10.1055/s-0034-1392366


Related references

Mo1096 Portable Inhaled Methoxyflurane for Colonoscopy in Patients With Morbid Obesity and/or Obstructive Sleep Apnoea Is Feasible and More Cost Effective Than Anaesthesia Assisted Approach. Gastroenterology 146(5): S-555-S-556, 2014

Gastro plasty for obstructive sleep apnea and morbid obesity. American Review of Respiratory Disease 125(4 PART 2): 108, 1982

Morbid obesity and women age are related to the obstructive sleep apnea syndrome. Sleep Medicine 14: E149-E150, 2013

Obstructive sleep apnea syndrome in morbid obesity: effects of intragastric balloon. Chest 128(2): 618-623, 2005

Obstructive sleep apnea, morbid obesity, and adenotonsillar surgery: a review of the literature. International Journal of Pediatric Otorhinolaryngology 69(11): 1475-1482, 2005

Nocturnal obstructive apnea as a cause of sleep deprivation and hyper somnolence in morbid obesity. American Review of Respiratory Disease 115(4 PART 2): 368, 1977

Gastroesophageal reflux in patients with morbid obesity: a role of obstructive sleep apnea syndrome?. Obesity Surgery 18(11): 1479-1484, 2008

Devices used in non-invasive ventilation for obstructive sleep apnea associating COPD and/or morbid obesity. Pneumologia 62(2): 106-109, 2013

Does the neutrophil-to-lymphocyte ratio have any importance between subjects with obstructive sleep apnea syndrome with obesity and without obesity?. Tuberkuloz Ve Toraks 66(1): 8-15, 2018

Obstructive sleep apnea severity is associated with left ventricular mass independent of other cardiovascular risk factors in morbid obesity. Journal of Clinical Sleep Medicine 9(11): 1165-1171, 2014

Impact of Bariatric Surgery on Heme Oxygenase-1, Inflammation, and Insulin Resistance in Morbid Obesity with Obstructive Sleep Apnea. Obesity Surgery 27(9): 2338-2346, 2017

Decrease of Plasma Soluble (Pro)renin Receptor by Bariatric Surgery in Patients with Obstructive Sleep Apnea and Morbid Obesity. Metabolic Syndrome and Related Disorders 16(4): 174-182, 2018

Endothelial Function of Patients with Morbid Obesity Submitted to Roux-en-Y Gastric Bypass With and Without Obstructive Sleep Apnea-Hypopnea Syndrome. Obesity Surgery 28(11): 3595-3603, 2018

Home Sleep Apnea Testing is a Feasible and Accurate Method to Diagnose Obstructive Sleep Apnea in Stroke Patients During In-Hospital Rehabilitation. Journal of Clinical Sleep Medicine 14(9): 1495-1501, 2018

Supraglottic jet oxygenation and ventilation assisted fiberoptic intubation in a paralyzed patient with morbid obesity and obstructive sleep apnea: a case report. Bmc Anesthesiology 19(1): 40, 2019